Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 181.64 | 141.91 | 132.82 | 108.05 | 96.60 |
Total Expenses | 197.81 | 147.14 | 120.39 | 109.44 | 92.73 |
Profit Before Tax | -16.16 | -4.69 | 12.43 | -0.37 | 3.86 |
Profit After Tax | -14.35 | -5.77 | 8.91 | -0.21 | 2.74 |
Operating Profit after Depreciation | -11.37 | -2.67 | 12.76 | -1.28 | 3.93 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 102.70 | 62.08 | 29.10 | 14.08 | 15.41 |
Total Non Current Assets | 116.71 | 73.94 | 62.19 | 24.26 | 29.61 |
Total Current Assets | 111.62 | 84.17 | 76.90 | 61.21 | 58.86 |
TOTAL ASSETS | 228.33 | 158.11 | 139.09 | 85.47 | 88.48 |
Total Shareholder's Fund | 89.98 | 80.36 | 89.63 | 66.30 | 68.83 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | -5.98 | -2.01 | 13.33 | -0.89 | 5.54 |
Net Cash used in Investing Activities | -12.90 | 14.70 | -26.65 | 3.82 | -3.53 |
Net Cash used in Financing Activities | 18.78 | -13.88 | 14.27 | -2.42 | -2.87 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 168.64 | 140.92 | 133.18 | 108.10 | 96.63 |
Total Expenses | 163.73 | 132.84 | 118.99 | 109.44 | 92.75 |
Profit Before Tax | 4.91 | 8.62 | 14.19 | -0.32 | 3.88 |
Profit After Tax | 3.38 | 6.59 | 10.58 | -0.16 | 2.76 |
Operating Profit after Depreciation | 5.27 | 8.15 | 14.26 | -1.23 | 3.95 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 11.94 | 11.45 | 12.56 | 13.99 | 15.41 |
Total Non Current Assets | 44.29 | 36.84 | 50.07 | 24.38 | 29.73 |
Total Current Assets | 128.99 | 87.80 | 75.21 | 61.13 | 58.76 |
TOTAL ASSETS | 173.28 | 124.64 | 125.28 | 85.52 | 88.49 |
Total Shareholder's Fund | 121.78 | 94.46 | 91.37 | 66.37 | 68.85 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | -30.14 | -10.29 | 13.66 | -0.84 | 5.55 |
Net Cash used in Investing Activities | -8.67 | 12.76 | -27.06 | 3.91 | -3.54 |
Net Cash used in Financing Activities | 38.08 | -3.79 | 14.27 | -2.47 | -2.97 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 67.28 | 56.30 | 49.64 | 46.93 | 45.27 |
Total Expenses | 68.15 | 57.56 | 51.12 | 43.60 | 40.84 |
Profit Before Tax | -12.69 | -12.16 | -9.50 | -2.74 | -1.11 |
Profit After Tax | -12.18 | -12.72 | -6.92 | -2.94 | -1.65 |
Operating Profit after Depreciation | -0.33 | -1.24 | -1.02 | 3.48 | 4.83 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 59.01 | 52.20 | 47.35 | 42.83 | 41.15 |
Total Expenses | 55.77 | 49.25 | 46.96 | 40.71 | 38.05 |
Profit Before Tax | 2.96 | 2.32 | 0.16 | 1.67 | 2.71 |
Profit After Tax | 2.35 | 1.58 | 0.22 | 1.16 | 1.79 |
Operating Profit after Depreciation | 4.21 | 3.42 | 1.08 | 2.50 | 3.73 |
₹1/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Zota Health Care Ltd | ₹948.85 | ₹2,600.57 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
10 Jan 2025, 03:58 pm
07 Jan 2025, 12:43 pm
09 Nov 2024, 02:45 pm
09 Sep 2024, 05:38 pm
09 Aug 2024, 04:39 pm